Bringing medicine back to life?
→
What We Do.
We turn great ideas into accessible medicines. To do that we work with academics to turn their ideas into reality and in a societally responsible manner. For us, this means building a sustainable business while ensuring patient access. Explore our portfolio to see how we realize that ambition.
→
Reformulating For Cystinosis
Repurposing For PXE
Repurposing For VWM
Academic Partners.
Insights.
EMA’s PRIME scheme: what it means for drug development
PRIME in drug development can shorten timelines, reduce costly late-stage surprises, and improve the chance of reaching patients. But the rejection rate is high and timing is critical. This article explains what PRIME actually offers and how to use it strategically.
Webinar: How do you design a clinical study that is registration-ready?
From protocol to registration: learn what changes when your endpoint is approval, not publication. Practical guidance on study design, CTIS readiness, GCP execution, and key post-study obligations.
Funding socially responsible drug development
Learn how to design a funding mix that gets your socially responsible drug from lab to patient, without losing sight of access and fair pricing.
Contact Orfenix.
For more information or to explore partnership opportunities, feel free to reach out to us anytime!
→
→ Follow us on LinkedIn
→ Meet the team